Cubist, Emisphere partner in oral delivery of daptomycin
Antimicrobial drug developer Cubist Pharmaceuticals will license oral drug delivery technology from Emisphere Technologies (oral delivery of large-molecule drugs) to apply to its Phase III antibiotic Cidecin (daptomycin), currently an injectable product, and other lipopeptides.
- Drug Delivery
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com